Workflow
BridgeBio Reports First Quarter 2025 Financial Results and Business Updates
BBIOBridgeBio(BBIO) GlobeNewswire News Room·2025-04-29 20:01

Core Insights - BridgeBio Pharma reported 36.7millioninnetproductrevenueforAttrubyinitsfirstfullquarter,with2,072uniquepatientprescriptionswrittenby756prescribersasofApril25,2025[1][2]−Thecompanyhasmadesignificantprogressinitsclinicaltrials,includingthefullenrollmentoftheobservationalrun−instudyforhypochondroplasiaPhase2trialaheadofschedule[1][6]−BridgeBioendedthequarterwith36.7 million in net product revenue for Attruby in its first full quarter, with 2,072 unique patient prescriptions written by 756 prescribers as of April 25, 2025 [1][2] - The company has made significant progress in its clinical trials, including the full enrollment of the observational run-in study for hypochondroplasia Phase 2 trial ahead of schedule [1][6] - BridgeBio ended the quarter with 540.6 million in cash and cash equivalents, excluding anticipated regulatory milestone payments of 105millionforex−U.S.approvalsofBEYONTTRA[1][9]CommercialProgress−ThefirstfullquarterofAttrubynetproductrevenuewas105 million for ex-U.S. approvals of BEYONTTRA [1][9] Commercial Progress - The first full quarter of Attruby net product revenue was 36.7 million, with 2,072 unique patient prescriptions written by 756 healthcare providers since FDA approval in November 2024 [2][13] - The Chief Commercial Officer highlighted a 42% reduction in all-cause mortality and a 50% decrease in cardiovascular hospitalizations at 30 months for patients treated with Attruby [3] Pipeline Overview - Acoramidis for ATTR-CM is approved in the U.S., EU, Japan, and UK, with the first participant in the ACT-EARLY Phase 3 trial expected to be dosed in 2025 [4] - BBP-418 for LGMD2I/R9 and encaleret for ADH1 have completed enrollment in their Phase 3 studies, with topline results expected in the second half of 2025 [4][6] - Infigratinib for achondroplasia is fully enrolled, with topline results anticipated in early 2026 [4][6] Key Program Updates - Attruby has shown strong clinical efficacy and safety, contributing to its growth in the ATTR-CM treatment paradigm [5][6] - The Phase 2 proof-of-principle study of encaleret in hypoparathyroidism showed 78% of participants achieving normal calcium levels within 5 days, with plans to advance to a registrational study in 2026 [6][7] Financial Updates - Cash and cash equivalents decreased to 540.6millionasofMarch31,2025,primarilyduetooperatingactivitiesandloanrepayments[9][10]−TotalrevenuesforthethreemonthsendedMarch31,2025,were540.6 million as of March 31, 2025, primarily due to operating activities and loan repayments [9][10] - Total revenues for the three months ended March 31, 2025, were 116.6 million, down from 211.1millioninthesameperiodthepreviousyear,mainlyduetoadecreaseinlicenseandservicesrevenue[10][11]−Thecompanyrecordedanetlossattributabletocommonstockholdersof211.1 million in the same period the previous year, mainly due to a decrease in license and services revenue [10][11] - The company recorded a net loss attributable to common stockholders of 167.4 million for the quarter, compared to a loss of $35.2 million for the same period in 2024 [20]